JNJ-89862175 / J&J - LARVOL DELTA

Discovery and preclinical characterization of a novel ENPP3-targeted ADC, JNJ-89862175 to treat advanced solid tumors (AACR 2026) - P1 | "In vivo, potent anti-tumor efficacy with complete tumor regressions was observed in a panel of lung and renal patient tumor derived xenograft models following single dose administration. JNJ-89862175 was well tolerated in preclinical non-human primate studies and demonstrated preferred pharmacokinetics.In summary, these preclinical data support the ongoing first-in-human Phase I trial (NCT07223125) to evaluate safety, tolerability, and preliminary antitumor activity of JNJ-89862175 in patients with ENPP3-expressing advanced solid tumors."

ADC • First-in-human • Metastases • Preclinical • Genito-urinary Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Uterine Cancer

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=360 | Recruiting | Sponsor: Janssen Research & Development, LLC

Trial initiation date • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Papillary Carcinoma

89862175LUC1001: A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors. (clinicaltrialsregister.eu) - P1 | N=120 | Recruiting | Sponsor: Janssen Cilag International

New P1 trial • Oncology • Solid Tumor

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=360 | Recruiting | Sponsor: Janssen Research & Development, LLC

New P1 trial • Solid Tumor